CTLA4 and cancer: Ongoing studies evaluating CPIs in HIV-associated cancers include a phase 1 study of nivolumab (anti-PD-1) combined with ipilimumab (anti-CTLA-4) in relapsed classical Hodgkin lymphoma or solid tumors (NCT02408861), a phase 2 study of nivolumab in advanced non-small cell lung cancer (NCT03304093), a phase 2 study of durvalumab in advanced cancer (NCT03094286), a study of pembrolizumab as first systemic therapy in KS (NCT02595866), and intralesional nivolumab for limited cutaneous KS (NCT03316274).